Alizé Pharma SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases, announces today the completion of two Phase I clinical trials with its unacylated ghrelin analog AZP-531 in 76 healthy volunteers and overweight or obese subjects.
↧
Alizé Pharma completes two Phase I clinical trials of AZP-531 in healthy volunteers, obese subjects
↧